WESTWOOD, MARTA KATARZYNA,SUTTON, BRIAN JOHN,MDONNELL, JAMES MICHAEL,LIU, XIAOFENG,HENRY, ALISTAIR JAMES,DAVIES, ANNA MARIE,CESKA, THOMAS ALLEN,ADAMS, RALPH
申请号：
ARP170101588
公开号：
AR108707A1
申请日:
2017.06.09
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
Claim 1: an anti IgE antibody or antigen binding agent, linked to a title that refers to the SEC ID. No. 108, t373, w374, s375, r376, a377, s378, g379, p381, q417, c418, r419, t421, p426, r427, a428 residues from a Ce3 domain and d278 and t281 residues from an IgE CE2 domain. 11. Claim 11: selectively select anti IgE antibody or antigen binding agent according to claims 1 to 10, including a variable heavy chain region, including a region for determining complementarity, namely CDR-H3, whose amino acid sequence is analyzed with d.d.d.d.a. of the U.S. Department of toxicology and disease registry. Number eighteenthAnd a variable light chain region, including a decisive complementary region, cdr-l1, has a series of amino acids with SEC ID. 29, wherein the light chain variable region also includes a framework region fr-l3, which contains the amino acid sequence selected from id.d.c. 32, which contains one, two, three, four, five, six, seven or more amino acid substitutes to enhance the interaction between antigen antibodies or polymerizers,Under the control of CE2 of the Institute of human studies Claim 104: a separate DNA sequence encoding the heavy and / or light chains of an antigen or antigen binding agent in accordance with items 1 to 103. Claim 105: a clone or expression vector containing one or more DNA sequences, consistent with claim 104. Claim 108: a host cell, consisting of one or more clones or expression vectors, complying with requirements 105 to 107 111: a pharmaceutical component including an antigen antibody or an antigen binding agent,Under claims 1 to 103, add one or more prostate glands, thinners or carriers that are medically acceptable. 123. Claim 123: anti IgE antibodies or antigenic binders referred to in claims 1 to 103, or ingredients referred to in claims 102 to 111 for the treatment or prevention of disorders related to IgE and FcERI complexes.Reivindicación 1: Un anticuerpo anti-IgE o agente de unión al antígeno, que se contacta con un epíto
